Aligos Therapeutics Inc.

ALGS | NASDAQ

Price Alert Chart Builder DCF Calculator

$6.04

+$0.55 (+10.02%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+10.02%

(1D)

Rating

Updated: Aug 24, 2026

27.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $37.37M

1D Range

5.22 6.29

52W Range

3.98 13.69

Valuation (TTM)

PE -0.77

PB 1.10

EV/EBITDA -0.11

Valuation (NTM)

Forward PE N/A

Forward PEG 0.04

Price Target $20

Cash Flow

FCF Yield -270.4%

SBC Adj. FCF Yield -286.4%

SBC Impact -5.9%

Margins

Gross Margin 99.2%

Operating Margin -250.6%

FCF Margin -299.9%

Growth (CAGR)

Revenue 3Y | 5Y 22.3% | 66.6%

Dil EPS 3Y | 5Y -28.3% | -34.9%

FCF 3Y | 5Y -5.4% | 2.9%

Returns

ROA -114.5%

ROE -160.7%

ROIC -191.7%

Financial Health

Net Cash

$30.38M

Current Ratio 2.19

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidat...

Sector Healthcare

Industry Biotechnology

Employees 82

IPO Date Oct 15, 2020

Website www.aligos.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+231.13%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞